Download PDF
Intensivmedizin up2date 2017; 13(01): 67-87
DOI: 10.1055/s-0042-122812
Neuro-Intensivmedizin
© Georg Thieme Verlag KG Stuttgart · New York

Nicht-Vitamin-K orale Antikoagulanzien in der Klinik

Corina Epple
,
Johannes Rosskopp
,
Thorsten Steiner
Further Information

Publication History

Publication Date:
23 February 2017 (online)

Also available at
    Permissions and Reprints All articles of this category

In den letzten Jahren werden NOAC zunehmend eingesetzt. Sie sind eine sichere und effektive Alternative zu den etablierten Vitamin-K-Antagonisten und weisen auch außerhalb der Studien weniger Blutungskomplikationen auf. Die wachsende Erfahrung mit den NOAC zeigt jedoch, dass noch Verbesserungsbedarf besteht und weitere Studien dringend erforderlich sind.
Kernaussagen

  • NOAC sind eine sichere und wirksame Therapie für Patienten, bei denen eine Langzeit-Antikoagulation erforderlich ist. Sie haben im Vergleich zu Vitamin-K-Antagonisten seltener Nebenwirkungen, kaum Wechselwirkungen mit Nahrungsmitteln oder Medikamenten und bieten den Vorteil einer fixen Dosierung.

  • Das Risiko für intrakranielle Blutungen ist bei NOAC um ca. 50 % geringer als bei Vitamin-K-Antagonisten.

  • Die klassischen Gerinnungstests helfen nur bei einigen NOAC weiter.

  • Für die Faktor-Xa-Inhibitoren ist die Situation noch schwieriger, da die meisten hilfreichen Testverfahren kaum verfügbar sind.

  • Spezifische Point-of-Care-Tests für NOAC sind in der klinischen Prüfung.

  • NOAC haben den Vorteil einer kurzen Halbwertszeit, weshalb bei leichten Blutungen eine abwartende Haltung und ggf. das zeitweilige Aussetzen der Medikation gerechtfertigt ist. Bei schweren Blutungen ist dagegen eine möglichst schnelle Wiederherstellung der Hämostase anzustreben.

  • Bei lebensbedrohlichen Blutungen oder nicht aufschiebbaren Eingriffen unter Dabigatran sollte man Idarucizumab in einer Dosierung von 5 g i. v. verabreichen.

  • Bei lebensbedrohlichen Blutungen oder nicht aufschiebbaren Eingriffen unter Faktor-Xa-Antagonisten sollte man die Gabe von PPSB (30 – 50 U/kgKG) erwägen.

  • Die Einnahme von Aktivkohle ist nach kurz zurückliegender Einnahme des Medikaments für alle Faktor-Xa-Inhibitoren eine Therapiemöglichkeit. Spezifische Antidota (Andexanet Alpha oder PER 977) sind in der klinischen Entwicklung.

  • Alle Patienten mit oraler Antikoagulationstherapie (Vitamin-K-Antagonisten und NOAC) sollten immer einen Notfallausweis bei sich tragen.

 

  • Literatur

  • 1 Patel NJ, Deshmukh A, Pant S. et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation 2014; 129: 2371-2379
    CrossrefPubMedSearch in Google Scholar
  • 2 Rizos T, Wagner A, Jenetzky E. et al. Paroxysmal atrial fibrillation is more prevalent than persistent atrial fibrillation in acute stroke and transient ischemic attack patients. Cerebrovascular Diseases (Basel, Switzerland) 2011; 32: 276-282
    CrossrefPubMedSearch in Google Scholar
  • 3 Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurology 2012; 11: 1066-1081
    CrossrefPubMedSearch in Google Scholar
  • 4 Cohen AT, Agnelli G, Anderson FA. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thrombosis and Haemostasis 2007; 98: 756-764
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Reilly PA, Lehr T, Haertter S. et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321-328
    CrossrefPubMedSearch in Google Scholar
  • 6 Holbrook A, Schulman S, Witt DM. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e152S-e184S
    CrossrefPubMedSearch in Google Scholar
  • 7 Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Int Med 1994; 120: 897-902
    CrossrefPubMedSearch in Google Scholar
  • 8 Franke CL, de Jonge J, van Swieten JC. et al. Intracerebral hematomas during anticoagulant treatment. Stroke 1990; 21: 726-730
    CrossrefPubMedSearch in Google Scholar
  • 9 Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. Journal of Thrombosis and Thrombolysis 2010; 29: 182-191
    CrossrefPubMedSearch in Google Scholar
  • 10 Heidbuchel H, Verhamme P, Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651
    CrossrefPubMedSearch in Google Scholar
  • 11 Steiner T, Bohm M, Dichgans M. et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clinical Research in Cardiology 2013; 102: 399-412
    CrossrefPubMedSearch in Google Scholar
  • 12 Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clinical Pharmacokinetics 2008; 47: 285-295
    CrossrefPubMedSearch in Google Scholar
  • 13 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and Haemostasis 2010; 103: 1116-1127
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Mueck W, Eriksson BI, Bauer KA. et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in patients undergoing major orthopaedic surgery. Clinical Pharmacokinetics 2008; 47: 203-216
    CrossrefPubMedSearch in Google Scholar
  • 15 Harenberg J, Erdle S, Marx S. et al. Determination of rivaroxaban in human plasma samples. Seminars in Thrombosis and Hemostasis 2012; 38: 178-184
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Tripodi A. The laboratory and the direct oral anticoagulants. Blood 2013; 121: 4032-4035
    CrossrefPubMedSearch in Google Scholar
  • 17 Kitchen S, Gray E, Mackie I. et al. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. Br J of Haematology 2014; 166: 830-841
    PubMedSearch in Google Scholar
  • 18 Rizos T, Herweh C, Jenetzky E. et al. Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke 2009; 40: 3547-3551
    Search in Google Scholar
  • 19 Ebner M, Peter A, Spencer C. et al. Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants. Stroke 2015; 46: 2741-2747
    CrossrefPubMedSearch in Google Scholar
  • 20 van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 2012; 125: 417-420
    CrossrefPubMedSearch in Google Scholar
  • 21 Härtig F, Peter A, Spencer C. et al. Specific Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants Part I (SPOCT-NOAC I). Stroke 2016; 47: A164
    PubMedSearch in Google Scholar
  • 22 Lip GY, Andreotti F, Fauchier L. et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011; 13: 723-746
    CrossrefPubMedSearch in Google Scholar
  • 23 Pernod G, Albaladejo P, Godier A. et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) March 2013. Archives of Cardiovascular Diseases 2013; 106: 382-393
    CrossrefPubMedSearch in Google Scholar
  • 24 Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Seminars in Neurology 2010; 30: 565-572
    Thieme ConnectPubMedSearch in Google Scholar
  • 25 Dowlatshahi D, Butcher KS, Asdaghi N. et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012; 43: 1812-1817
    CrossrefPubMedSearch in Google Scholar
  • 26 Flibotte JJ, Hagan N, O‘Donnell J. et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63: 1059-1064
    CrossrefPubMedSearch in Google Scholar
  • 27 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
    CrossrefPubMedSearch in Google Scholar
  • 28 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
    CrossrefPubMedSearch in Google Scholar
  • 29 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
    CrossrefPubMedSearch in Google Scholar
  • 30 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
    CrossrefPubMedSearch in Google Scholar
  • 31 Epple C, Steiner T. Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat?. Expert Opinion on Pharmacotherapy 2014; 15: 1991-2001
    CrossrefPubMedSearch in Google Scholar
  • 32 Hart RG, Diener HC, Yang S. et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517
    CrossrefPubMedSearch in Google Scholar
  • 33 Zhou W, Schwarting S, Illanes S. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599
    CrossrefPubMedSearch in Google Scholar
  • 34 Zhou W, Zorn M, Nawroth P. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44: 771-778
    CrossrefPubMedSearch in Google Scholar
  • 35 Purrucker JC, Haas K, Rizos T. et al. Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants. JAMA Neurology 2016; 73: 169-177
    CrossrefPubMedSearch in Google Scholar
  • 36 Marlu R, Hodaj E, Paris A. et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thrombosis and Haemostasis 2012; 108: 217-224
    Thieme ConnectPubMedSearch in Google Scholar
  • 37 Frontera JA, Lewin 3rd JJ, Rabinstein AA. et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Crit Care Med. Neurocritical Care 2016; 24: 6-46
    CrossrefPubMedSearch in Google Scholar
  • 38 Khadzhynov D, Wagner F, Formella S. et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thrombosis and Haemostasis 2013; 109: 596-605
    Thieme ConnectPubMedSearch in Google Scholar
  • 39 Vigue B, Ract C, Tremey B. et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007; 33: 721-725
    CrossrefPubMedSearch in Google Scholar
  • 40 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (London, England) 2014; 383: 955-962
    CrossrefPubMedSearch in Google Scholar
  • 41 May A, Farber M, Aschmoneit I. et al. Prospective multicenter trial comparing push-and-pull enteroscopy with the single- and double-balloon techniques in patients with small-bowel disorders. Am J of Gastroenterology 2010; 105: 575-581
    PubMedSearch in Google Scholar
  • 42 Lim LG, Ho KY, Chan YH. et al. Urgent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleeding. Endoscopy 2011; 43: 300-306
    Thieme ConnectPubMedSearch in Google Scholar
  • 43 Liew A, Eikelboom JW, O'Donnell M. et al. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. The Canadian Journal of Cardiology 2013; 29 (Suppl. 07) S34-44
    CrossrefPubMedSearch in Google Scholar
  • 44 Seet RC, Zhang Y, Moore SA. et al. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke 2011; 42: 2333-2335
    CrossrefPubMedSearch in Google Scholar
  • 45 Steiner T, Poli S, Griebe M. et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurology 2016; 15: 566-573
    CrossrefPubMedSearch in Google Scholar
  • 46 Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thrombosis and Haemostasis 2015; 113: 931-942
    Thieme ConnectPubMedSearch in Google Scholar
  • 47 Pollack Jr CV, Reilly PA. et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-520
    CrossrefPubMedSearch in Google Scholar
  • 48 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Medicine 2013; 19: 446-451
    CrossrefPubMedSearch in Google Scholar
  • 49 Crowther MA, Levy G, Lu G. et al. ANNEXA™-A: A Phase 3 Randomized,Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. AHA presentation Nov 2014. Circulation 2014; 130: 2105-2126
    CrossrefPubMedSearch in Google Scholar
  • 50 O‘Riordan M. Positive Results for Factor Xa Inhibitor Antidote: ANNEXA-A. 2014 Im Internet: http://www.medscapecom/viewarticle/832648 [Stand: 07.04.2016
    PubMedSearch in Google Scholar
  • 51 Connolly SJ, Milling Jr TJ, Eikelboom JW. et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2016; 375: 1131-1141
    CrossrefPubMedSearch in Google Scholar
  • 52 Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace 2016; 18: 955-964
    CrossrefPubMedSearch in Google Scholar
  • 53 Ansell JE, Bakhru SH, Laulicht BE. et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371: 2141-2142
    CrossrefPubMedSearch in Google Scholar
  • 54 Laulicht B, Bakhru S, Jiang X. et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Amsterdam: 24th Congress of the International Society on Thrombosis and Haematosis; 2013
    PubMedSearch in Google Scholar
  • 55 Kuramatsu JB, Gerner ST, Schellinger PD. et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313: 824-836
    CrossrefPubMedSearch in Google Scholar
  • 56 Ansell J. Is there a need for an alternative in the era of novel anticoagulants?. Expert Review of Cardiovascular Therapy 2015; 13: 967-970
    CrossrefPubMedSearch in Google Scholar